Back to results
US 2019/0056403 A1Published application
Lung cancer signature
AssigneeThe Regents of the University of Michigan
InventorsVenkateshwar G. Keshamouni, Gilbert S. Omenn, Guoan Chen, David G. Beer, Theodore J. Standiford
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.
Claims6
1-15. (canceled)
A method for determining a prognosis of a subject diagnosed with lung cancer, comprising:
- contacting a sample from a subject diagnosed with lung with reagents for detection of altered expression of one or more genes selected from the group consisting of of HMGA2, LAMC2, EIF4EBP1, FN1, HSPB1, ULBP2, VEGFA, BMP1, FST, CD59, TNFRSF12A, PDGFB, COL4A3, SERPINE1, SCG2, TGFB1, HMOX1, STC1, XYLT1, and PPP1R14B.
Dependencies are inferred from the claim text.